Our regression analysis showed that, in adult patients with moderate-to-severe hemophilia A, the level of FVIII decreases to 0.01 IU/mL after about 5.4 days from the last Elocta® injection, highlighting that the prophylactic dose of Elocta® can be given up to every five days. The gene discussed is F8; the disease is hemophilia A.